Expert panel says new $56K Alzheimer’s drug is unproven—and worth $8400 max – Ars Technica
Enlarge/ The exterior of the headquarters of biotechnology company Biogen in Cambridge, Massachusetts.
47 with 37 posters participating
Biogen’s new Alzheimer’s drug Aduhelm continues to face opposition after its contentious approval by the Food and Drug…
